Prognostic Fifteen-Gene Signature for Early Stage Pancreatic Ductal Adenocarcinoma

Dung-Tsa Chen, Ashley H Davis-Yadley, Po-Yu Huang, Kazim Husain, Barbara A Centeno, Jennifer Permuth-Wey, Jose M Pimiento and Mokenge Malafa

PLOS ONE, 2015, vol. 10, issue 8, 1-17

Abstract: The outcomes of patients treated with surgery for early stage pancreatic ductal adenocarcinoma (PDAC) are variable with median survival ranging from 6 months to more than 5 years. This challenge underscores an unmet need for developing personalized medicine strategies to refine the current treatment decision-making process. To derive a prognostic gene signature for patients with early stage PDAC, a PDAC cohort from Moffitt Cancer Center (n = 63) was used with overall survival (OS) as the primary endpoint. This was further evaluated using an independent microarray cohort dataset (Stratford et al: n = 102). Technical validation was performed by NanoString platform. A prognostic 15-gene signature was developed and showed a statistically significant association with OS in the Moffitt cohort (hazard ratio [HR] = 3.26; p

Date: 2015
References: Add references at CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0133562 (text/html)
https://journals.plos.org/plosone/article/file?id= ... 33562&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pone00:0133562

DOI: 10.1371/journal.pone.0133562

Access Statistics for this article

More articles in PLOS ONE from Public Library of Science
Bibliographic data for series maintained by plosone ().